期刊文献+

CLINICAL STUDY IN ACCELERATED HYPERFRACTIONATED IRRADIATION IN THE TREATMENT OF LOCAL ADVANCED NON-SMALL CELL LUNG CANCER 被引量:1

CLINICAL STUDY IN ACCELERATED HYPERFRACTIONATED IRRADIATION IN THE TREATMENT OF LOCAL ADVANCED NON-SMALL CELL LUNG CANCER
下载PDF
导出
摘要 Objective To evaluate the effect of accelerated hyperfractionated irradiation (AHFJ) and conventional fractionated irradiation (CFI) for local advanced non- small cell lung cancer (NSCLC). Methods The patients of AI-IFJ group were irradiated to large-field target volume by a daily fraction of 2Gy, and small-field target volume by a daily fraction of 1Gy with more than 6h interval. The total dose of large-field target volume was SOGy/25Fx/SW and of small-field target volume was 7SGy/SOFx/5W. The patients in CFI group were irradiated by a daily fraction of 2Gy to the total dose of 66Gy/33Fx/6. 6W. After 3 months of radiotherapy, the tumor response rates of complete recovery (CR), partial recovery (PR), and no change (NC) and 1- and 2- year survival rate in the two groups were observed. Results The tumor response rates of CR,PR,NC in AHFI group and CFI group were 22.9%(8/35), 60.0%(21/35), 17.1%(6/35) and 11.4% (4/35), 51.4% (18/35), 37.2% (13/35) respectively (P>0. 05). All patients were followed up 2 years or more. The 1- and 2- year survival rates in AHFI group and CFI group were 62.9% (22/35), 31 .4% (11/35) and 42.9% (15/35) , 17.1% (6/35) respectively (P< 0.05). The incidences of esophagitis and pneumonitis in AHFI group and CFI group were 34.3% (12/35), 22. 9% (8/35) and 40.0% (14/35), 17.1% (6/35)(P>0. 05). Conclusion In comparison with CFI, AHFI may increase 1- and 2- year sur-vival rate after treatment of local advanced non-small cell lung cancer, while the radio-reactions, either early or late, did not increase significantly. Objective To evaluate the effect of accelerated hyperfractionated irradiation (AHFJ) and conventional fractionated irradiation (CFI) for local advanced non- small cell lung cancer (NSCLC). Methods The patients of AI-IFJ group were irradiated to large-field target volume by a daily fraction of 2Gy, and small-field target volume by a daily fraction of 1Gy with more than 6h interval. The total dose of large-field target volume was SOGy/25Fx/SW and of small-field target volume was 7SGy/SOFx/5W. The patients in CFI group were irradiated by a daily fraction of 2Gy to the total dose of 66Gy/33Fx/6. 6W. After 3 months of radiotherapy, the tumor response rates of complete recovery (CR), partial recovery (PR), and no change (NC) and 1- and 2- year survival rate in the two groups were observed. Results The tumor response rates of CR,PR,NC in AHFI group and CFI group were 22.9%(8/35), 60.0%(21/35), 17.1%(6/35) and 11.4% (4/35), 51.4% (18/35), 37.2% (13/35) respectively (P>0. 05). All patients were followed up 2 years or more. The 1- and 2- year survival rates in AHFI group and CFI group were 62.9% (22/35), 31 .4% (11/35) and 42.9% (15/35) , 17.1% (6/35) respectively (P< 0.05). The incidences of esophagitis and pneumonitis in AHFI group and CFI group were 34.3% (12/35), 22. 9% (8/35) and 40.0% (14/35), 17.1% (6/35)(P>0. 05). Conclusion In comparison with CFI, AHFI may increase 1- and 2- year sur-vival rate after treatment of local advanced non-small cell lung cancer, while the radio-reactions, either early or late, did not increase significantly.
出处 《Journal of Shanghai Second Medical University(Foreign Language Edition)》 2001年第1期59-62,共4页 上海第二医科大学学报(英文版)
关键词 advanced non-small cell lung cancer accelerated hyperfractionated irradiation therapy conventional fractionated irradiation therapy advanced non-small cell lung cancer accelerated hyperfractionated irradiation therapy conventional fractionated irradiation therapy
  • 相关文献

参考文献7

  • 1Saunders MI,Dische S.Barrett A, at al.Randomized multicen-tre trials of CHART vs conventional radiotherapy in head and neck and non-small cell lung cancer: an interim report[].British Journal of Cancer.1996
  • 2Cox JD,Azarnia N,Byhardt RW,et al.N2 (clinical) non-small cell carcinoma of the lung: prospective trials of radiation therapy with toed doses 60Gy by the Radiation Therapy Oncology Group[].International Journal of Radiation Oncology Biology Physics.1991
  • 3Brindle JS,Shaw EG,Su JQ,et al.Pilot study of accelerated hy-perfractionated thoracic radiation therapy in patients with unre-sectable stage Ⅲ non-small cell lung carcinoma[].Cancer.1993
  • 4Choy H,Akerley W,Safran H,et al.Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small cell lung cancer[].Journal of Clinical Oncology.1998
  • 5Choy H,Safran H,Akerley W,et al.Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer[].Clinical Cancer Research.1998
  • 6Saunders MI,Dische S.Barrett A, at al.Continuous hyperfrac-tionated accelerated radiotherapy (CHART) in non-small cell lungcarcinoma of the bronchus[].International Journal of Radiation Oncology Biology Physics.1990
  • 7Hardt RW,Pajak TF,Emami B,at al.A phase I /Ⅱ study to evaluate accelerated fraction via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07[].International Journal of Radiation Oncology Biology Physics.1993

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部